EXOSC2 inhibitors represent a class of chemical compounds designed to selectively target EXOSC2, one of the core subunits of the exosome complex. The exosome is a highly conserved, multi-protein complex responsible for RNA processing and degradation in eukaryotic cells. EXOSC2, also known as ribosomal RNA-processing protein 4 (RRP4), plays a crucial role in this complex by contributing to the structural integrity and function of the exosome. The exosome complex itself is essential for maintaining cellular homeostasis by regulating the quality and quantity of various RNA species. Therefore, inhibitors specifically targeting EXOSC2 are designed to modulate the exosome's activity, primarily impacting RNA metabolism within the cell.
The mechanism of action of EXOSC2 inhibitors typically involves binding to EXOSC2 or disrupting its function within the exosome complex. By doing so, these inhibitors can interfere with the normal processing and degradation of RNA molecules, leading to alterations in the RNA landscape of the cell. This, in turn, can have wide-ranging effects on gene expression, post-transcriptional regulation, and the cellular response to various environmental cues. Importantly, EXOSC2 inhibitors are valuable tools in research settings, allowing scientists to investigate the role of the exosome and RNA metabolism in cellular processes and diseases. Understanding how these inhibitors impact RNA processing and degradation can shed light on the fundamental mechanisms governing gene expression.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $203.00 $611.00 | 24 | |
Inhibits sphingomyelinases, disrupting lipid composition and exosome biogenesis. | ||||||
Amiloride, 5-(N,N-Dimethyl)-, hydrochloride | 2235-97-4 | sc-202459 | 5 mg | $235.00 | 7 | |
Blocks acid sphingomyelinase activity, impeding exosome secretion by altering lipid metabolism. | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $219.00 $634.00 | 5 | |
Disrupts Ras signaling pathways, affecting exosome release mediated by the Ras-MEK-ERK pathway. | ||||||
Spliceostatin A | 391611-36-2 | sc-507481 | 1 mg | $1800.00 | ||
Inhibits spliceosome activity, leading to altered RNA processing and reduced exosome cargo. | ||||||
GW 0742 | 317318-84-6 | sc-203991 sc-203991A | 10 mg 50 mg | $194.00 $831.00 | 11 | |
Activates PPARβ/δ, regulating exosome biogenesis and secretion. | ||||||
YM 155 | 781661-94-7 | sc-364661 sc-364661A | 5 mg 25 mg | $132.00 $507.00 | 3 | |
Downregulates survivin, affecting exosome cargo and release related to apoptotic pathways. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
Disrupts RNA synthesis, leading to altered exosome RNA content and secretion. | ||||||
Dexrazoxane | 24584-09-6 | sc-252669 | 5 mg | $112.00 | 1 | |
Inhibits topoisomerase II, disrupting DNA packaging into exosomes and their cargo. | ||||||
Thioridazine | 50-52-2 | sc-473180 | 50 mg | $500.00 | ||
Alters endosomal pH and membrane integrity, affecting exosome secretion through endocytic pathways. | ||||||